REGISTER NOW

Join Dr. Laia Montoliu-Gaya, Assistant Professor from the University of Gothenburg, as she discusses recent advancements in Simoa® assays, designed to aid Alzheimer’s disease diagnosis and staging and expand access to broader populations.

Gain insight into the current state of the field, with a focus on Simoa assay development and application, as well as the technical innovations and strategic approaches scientists are using to drive progress.

Key learning objectives

• Explore the recent developments in Simoa immunoassays
• Learn about innovative applications and sample collection systems
• Explore the application of both established and new Simoa biomarkers in Alzheimer’s disease
• Learn more about expanding access to blood biomarkers for broader populations

Who should attend?

• Neurology department heads and clinical directors
• Research directors and principal investigators
• Laboratory managers and diagnostics supervisors
• Biotech and pharma R&D executives
• Product development managers in medical diagnostics
• Senior researchers in neurodegenerative disease
• Clinical trial managers and coordinators
• University research department: researchers, leads, chairs, and program directors

Speaker

Dr. Laia Montoliu-GayaAssistant Professor, University of Gothenburg, Sweden

Dr. Laia Montoliu-Gaya, Assistant Professor at the University of Gothenburg, Sweden, is the inventor of a unique mass spectrometry method to detect tau species in blood for the diagnosis of Alzheimer’s disease. In addition, she is a co-inventor of a digital immunoassay for the quantification of p-tau205 in human biofluid and has also performed extensive work in diagnosing Alzheimer’s disease in individuals with Down syndrome.

REGISTER NOW